



**Quarterly Formulary Changes Announced (Second Quarter 2026)**

Quarterly changes to the Independent Health Drug formularies are summarized below and are currently in effect unless otherwise noted.

NPG/NPB - Non-Preferred Generic/Brand  
 PG/PB - Preferred Generic/Brand  
 NF - Non-Formulary  
 SP - Specialty Pharmacy  
 PA - Prior Authorization  
 ST - Step Therapy

QL – quantity Limits  
 SC – subcutaneous  
 IM - intramuscular  
 inj – injection  
 tab – tablet  
 cap – capsule  
 oph- ophthalmic

soln – solution  
 susp – suspension  
 MDI-metered-dose inhalation aerosol  
 ODT – orally-disintegrating tablet  
 LA-available only at certain pharmacies  
 G- Generic (T2) for Medicare

<b>Changes to Drug Formulary I (DF1), FEHB Formulary, and Pharmacy Benefit Dimensions Formulary</b>		
<b>Medications Added to Formulary 7/1/2026</b>	<b>Medications Non-Formulary 7/1/2026</b>	<b>Changes to Formulary 10/1/2026</b>
Idvynso (doravirine/islatravir) tab NPB Lifyorli (relacorilant) cap NPB, PA Veppanu (vepedegestrant) tab NPB, PA Beqalzi (sonrotoclast) tab NPB, PA	Awiqli (insulin icodex-abae) SC Yuviwel (navepegritide) SC w/PA Foundayo (orforglipron) tab – added to PA policy Lynavoy (linexibat) tab w/PA Icotyde (icotrokinra) tab w/PA Bysanti (milsaperidone) tab	bromfenac 0.07% - T3 ST to T1 bromfenac 0.09% - T1 to NF loteprednol 0.5% - add to T1 brimonidine 0.1% - T1 to T3 brimonidine 0.15% - T1 to T2 brinzolamide 1% - T1 to T3 Maxidex 0.1% - T3 to NF Inveltys 1% - T3 to NF timolol GFS 0.25% - T1 to T3 timolol GFS 0.5% - T1 to T3 bepotastine 1.5% - T3 ST to NF epinastine 0.05% - T1 to NF Alocril 2% - T3 ST to NF Zirgan 0.15% - T2 to NF ciprofloxacin-hydrocortisone susp- T3 PA to NF NP thyroid- T1 to T3 Armour thyroid- T2 to T3

<b>Changes to Drug Formulary II (DF2), Drug Formulary III (DF3), and Essential Plan Formulary (EPF)</b>		
<b>Medications Added to Formulary 7/1/2026</b>	<b>Medications Non-Formulary 7/1/2026</b>	<b>Changes to Formulary 10/1/2026</b>
Idvynso (doravirine/islatravir) tab NPB Lifyorli (relacorilant) cap NPB, PA Veppanu (vepedegestrant) tab NPB, PA Beqalzi (sonrotoclast) tab NPB, PA	Awiqli (insulin icodex-abae) SC Yuviwel (navepegritide) SC w/PA Foundayo (orforglipron) tab – added to PA policy Lynavoy (linexibat) tab w/PA Icotyde (icotrokinra) tab w/PA Bysanti (milsaperidone) tab	bromfenac 0.07% - T3 ST to T1 bromfenac 0.09% - T2 to NF loteprednol 0.5% - add to T1 brinzolamide 1% - T2 to T3 Maxidex 0.1% - T3 to NF Inveltys 1% - T3 to NF timolol GFS 0.25% - T1 to T3 timolol GFS 0.5% - T1 to T3 bepotastine 1.5% - T3 ST to NF epinastine 0.05% - T1 to NF Alocril 2% - T3 ST to NF Zirgan 0.15% - T3 to NF ciprofloxacin-hydrocortisone susp- T3 PA to NF NP thyroid- T1 to T3 Armour thyroid- T2 to T3

<b>Changes to Child Health Plus Formulary</b>		
<b>Medications Added to Formulary 7/1/2026</b>	<b>Medications Non-Formulary 7/1/2026</b>	<b>Changes to Formulary 10/1/2026</b>
	Awiqli (insulin icodex-abae) SC Yuviwel (navepegritide) SC Foundayo (orforglipron) tab – BLOCK Lynavoy (linexibat) tab Icotyde (icotrokinra) tab Bysanti (milsaperidone) tab Idvynso (doravirine/islatravir) tab Lifyorli (relacorilant) cap Veppanu (vepedegestrant) tab Beqalzi (sonrotoclast) tab	bromfenac 0.07% - add to T1 bromfenac 0.09% - T1 to NF loteprednol 0.5% - add to T1 epinastine 0.05% - T1 to NF

<b>Changes to Medicare Formulary</b>		
<b>Medications Added to Formulary 7/1/2026</b>	<b>Medications Non-Formulary 7/1/2026</b>	<b>Changes to Formulary /1/2026</b>
Idvynso (doravirine/islatravir) tab NPB Lifyorli (relacorilant) cap NPB, PA Veppanu (vepedegestrant) tab NPB, PA Beqalzi (sonrotoclast) tab NPB, PA	Awiqli (insulin icodex-abae) SC Yuviwel (navepegritide) SC Foundayo (orforglipron) tab – BLOCK Lynavoy (linexibat) tab Icotyde (icotrokinra) tab Bysanti (milsaperidone) tab	Attruby- added T5 PA (4/10/26) Breztri- added T3 (4/1/26) Repatha- removed prescriber restriction to cardiology and endocrinology (7/1/26)

**Medical with PA: (effective 7/1/2026)**

1. Loargys (pegzilarginase-nbln) IV or SC
2. Avlayah (tividenofusp alfa-eknm) IV
3. Kresladi (marnetegrane autotemcel) IV
4. Otarmeni (lunsotogene parvec-cwha) susp for intracochlear infusion

**Expedited reviews:**

Brand name	Generic name	Indication(s)	Coverage
Desmoda	desmopressin	management of central diabetes insipidus as antidiuretic replacement therapy	NF
Atoncy	atomoxetine	treatment of ADHD in patients 6 years of age and older	NF
Filspari	sparsentan	to reduce proteinuria in patients 8 years of age and older with focal segmental glomerulosclerosis without nephrotic syndrome	PA policy change

**Policy updates of drugs with new indications:**

Brand name	Generic name	New indication(s)	Coverage changes
Alyftrek	deutivacaftor/tezacaftor/vanzacaftor	<i>F508del</i> mutation wording eliminated from indication	n/a
Arexvy	RSV vaccine, adjuvanted	lower AL in at-risk patients down to 18 years of age	AL changes
Asceniv	immune globulin IV, human-sira	lower AL down to 2 years of age	n/a
Auvelity	bupropion/dextromethorphan	agitation associated with dementia due to AD	PA policy changes
Bizengri	zenocutuzumab-zbco	cholangiocarcinoma with <i>NRG1</i> gene fusion	PA policy updates
Breztri	budesonide/glycopyrrolate/formoterol	asthma	AL changes
Caldolor	ibuprofen injection	postoperative pain	n/a
Cosentyx	secukinumab	ankylosing spondylitis lower AL down to 12 years	PA policy changes
Cosentyx	secukinumab	hidradenitis suppurativa 12 years of age and up	PA policy changes
Darzalex Faspro	daratumumab/hyaluronidase-fihj	R/R MM after 1+ line of therapy w/teclistamab	PA policy changes
Dupilixent	dupilumab	allergic fungal rhinosinusitis after surgery	PA policy changes
Dupilixent	dupilumab	CSU lower AL down to 2 years of age	PA policy changes
Fasenra	benralizumab	hypereosinophilic syndrome	PA policy updates
Imcivree	setmelanotide	acquired hypothalamic obesity ages 4 and up	PA policy changes
Inqovi	decitabine/cedazuridine	w/venetoclax, AML if $\geq 75$ y.o. or comorbidities	PA policy updates
Juxtapid	lomitapide	lower AL down to 2 years of age	PA policy changes
Licart	diclofenac epolamine patches	lower AL down to 6 years of age	n/a
neffy	epinephrine nasal spray	lower AL removed from indication	AL changes
Ocrevus	ocrelizumab	RRMS in pediatric patients 10 years of age and older	PA policy updates
Opdivo	nivolumab	previously untreated cHL with AVD combination	PA policy changes
Palynziq	pegvaliase-pqpz	lower AL down to 12 years of age	PA policy changes
Prezcobix	darunavir/cobicistat	can be used down to $\geq 15$ kg and 3 years of age	AL changes
Rizafilm	rizatriptan oral film	lower AL down to 6 years of age	n/a
Sogroya	somapacitan-beco	growth failure associated with Noonan syndrome	PA policy changes
Sogroya	somapacitan-beco	idiopathic short stature	PA policy changes
Sogroya	somapacitan-beco	short stature born small for gestational age	PA policy changes
Sotyktu	deucravacitinib	psoriatic arthritis in adults	PA policy changes
Stelara	ustekinumab	pediatric Crohn's disease down to 2 years of age	PA policy changes
Symbicort Aero	budesonide/formoterol	asthma	n/a
Tecvayli	teclistamab-cqyv	R/R MM after 1+ line of therapy w/Darzalex Faspro	PA policy changes
Trikafta	elexacaftor/tezacaftor/ivacaftor	<i>F508del</i> mutation in <i>CFTR</i> added to indication	PA policy changes
Tzield	teplizumab-mzwv	lower AL down to 1 year of age	PA policy changes
Vyvgart	efgartigimod alfa-fcab	anti-AChR-Ab seronegative gMG	PA policy updates
Vyvgart Hytrulo	efgartigimod alfa/hyaluronidase-qvfc	anti-AChR-Ab seronegative gMG	PA policy updates
Wellcovorin	leucovorin tablets	cerebral folate transport deficiency	n/a
Zerbaxa	ceftolozane/tazobactam	HABP/VABP lower AL drop $\geq 32$ wk gestational age	PA policy updates

**New generics:**

Brands now non-formulary unless otherwise indicated. For Medicaid, medical drugs will be covered as Commercial unless otherwise specified below.

Brand name	Generic name	Generic tier placement and utilization management			
		Commercial/FEHB	Exch/Small/EBP	Medicaid	Medicare Indiv/PDP
Astagraf XL	tacrolimus ER	T3	T3	NF	T4 (NF STD)/T1
Atrovent HFA	ipratropium	T2	T2	T1	T4/T1
Briviact	brivaracetam	T2 PA exc neuro	T2 PA exc neuro	NF	T5/T1
Edarbi	azilsartan	NF	NF	NF	NF/NF
Farxiga	dapagliflozin	T1	T1	NF	T2/T1
Incruse	<i>authorized generic only</i>	NF	NF	NF	NF/NF
Lumigan	bimatoprost 0.01%	NF	NF	NF	NF/NF
Nitro-Bid	nitroglycerin ointment 2%	T3	T2	T1	T4 (NF STD)/T1
Nucynta/ER	tapentadol/ER	NF/NF	NF/NF	NF/NF	NF/NF//NF/NF
Ofev	nintedanib	T3 PA	T3 PA	NF	T5 PA/T1 PA
Savella	milnacipran	NF	NF	NF	T3 (T4 STD)/T1
Xigduo XR	dapagliflozin/metformin	T1	T1	NF	T2/T1

**Biosimilar drug changes:**

Biosimilar (generic name)	Reference Product	Changes	Effective date
Ponlimsi (denosumab-adet)	Prolia	Medical, ST (non-preferred)	7/1/2026
Langlara (insulin glargine-aldy)	Lantus	NF	7/1/2026

**Products removed from market**

- Roctavian (valoctocogene roxaparvovec-rvox) 2/23/2026
- Tazverik (tazemetostat) 3/9/2026

**2027 Proposed Medicare Formulary Changes**

**Formulary deletions (both ENH and STD)**

- almotriptan (NF on STD 2026)
- apomorphine SC cartridges (NF on STD 2026)
- Aqneursa
- Aralast NP
- Betoptic-S (NF on STD 2026)
- butalbital-acetaminophen
- butalbital-acetaminophen-caffeine-codeine
- butalbital-aspirin-caffeine-codeine
- Bylvay (NF on STD 2026)
- cefotaxime IV
- chlordiazepoxide
- chlordiazepoxide-amitriptyline
- Cholbam
- clindamycin 1% gel (once-daily)
- clonidine ER (for ADHD, NF on STD 2026)
- Corlanor oral solution (NF on STD 2026)
- Danziten
- deferiprone
- desvenlafaxine ER (generic Khedezla)
- dextrose 5% in lactated Ringers IV
- diclofenac patch (NF on STD 2026)
- Entresto sprinkle capsule
- Ervebo
- erythromycin ethylsuccinate 400 mg tab
- erythromycin lactobionate IV
- Fabhalta (NF on STD 2026)
- Femring (NF on STD 2026)
- fenofibric acid 35 mg, 105 mg
- Fiasp
- Firdapse
- fluoxetine 90 mg DR capsule
- flurbiprofen
- fluticasone-salmeterol (AirDuo gen., NF on STD 2026)
- glucagon HCl emergency solution

- hydrocodone ER tab (NF on STD 2026)
- hydromorphone preservative-free injection
- hydroxyzine pamoate 100 mg cap
- insulin aspart
- lactated Ringers IV
- levofloxacin IV
- Lo-Loestrin Fe (NF on STD 2026)
- Lodoco (NF on STD 2026)
- Lupron Depot (only matches to formulary products)
- memantine titration pack
- Methitest
- methscopolamine (NF on STD 2026)
- methylphenidate chewable tab (NF on STD 2026)
- methylphenidate ER tablets (NF on STD 2026)
- methyltestosterone
- montelukast powder packets
- morphine IV
- moxifloxacin IV
- naloxone nasal spray (Narcan generic – all OTC)
- nizatidine (NF on STD 2026)
- Novolog
- Nuversa
- olopatadine ophthalmic solution
- paricalcitol 4 mcg capsule
- pentazocine-naloxone (NF on STD 2026)
- Pheburane (NF on STD 2026)
- potassium-dextrose 5% in water IV
- potassium-dextrose 5% in water-lactated Ringers IV
- pretomanid
- Privigen
- Recorlev
- Rezdiffra
- ribavirin inhalation solution
- Ringers IV
- Sivextro
- Slynd
- Sohonos (NF on STD 2026)
- Stelara
- Tavneos (NF on STD 2026)
- testosterone gel (2 specific products NF on STD 2026)
- timolol ophth preservative-free (NF on STD 2026)
- Tresiba
- Velsipity
- Voydeya (NF on STD 2026)
- Vyndamax
- Xarelto
- Xuriden

- Zilbrysq (NF on STD 2026)
- zolmitriptan orally-disintegrating tab

#### ***Formulary deletions (STD only)***

- Combipatch
- Envarsus XR
- mupirocin cream
- Opsumit
- Vanrafia
- Viberzi

#### ***Negative changes (both ENH and STD)***

- acamprosate to T3
- Aimovig add QL
- alendronate oral solution to T4
- amphet-D-amphet ER cap to T4, add QL (NF on STD)
- amphet-D-amphet tab add QL
- auranofin to T5
- benzotropine add PA
- betamethasone dipropionate augmented gel to T4
- carbamazepine ER cap to T4 (T4 on STD 2026)
- Cerdelga add QL
- citalopram oral solution to T4 (T4 on STD 2026)
- clindamycin-dextrose 5% in water IV to T4
- clobazam oral suspension to T4 (T4 on STD 2026)
- cyclobenzaprine add PA
- Cystagon to T4 (T4 on STD 2026)
- diclofenac 1.5% topical solution to T4, add QL
- diclofenac sodium DR 25 mg to T4, add QL
- diclofenac sodium ER 100 mg to T4
- difluprednate ophth emulsion to T4
- digoxin oral solution to T4
- dihydroergotamine nasal spray add ST
- Eliquis 2.5 mg and starter pack add QL
- EluRyng/EnilloRing/generic to T3 (T3 on STD 2026)
- Emsam 6 and 9 mg patches add QL
- emtricitabine to T3
- ergotamine-caffeine tab to T3 (T3 on STD 2026)
- everolimus 0.25 mg tab add QL
- everolimus soluble tab (cancer indication) add QL
- everolimus tab (cancer indication) add QL
- Fanapt titration packs change to annual QL
- felbamate oral suspension to T4 (T4 on STD 2026)
- Firmagon 80 mg to T4
- Firmagon 120 mg to T5
- fluoxetine oral solution to T4 (T4 on STD 2026)
- fondaparinux 2.5 mg to T4
- glucagon regular solution to T3

- hydroxyzine HCl and pamoate add PA
- imipenem-cilastatin IV to T4
- ketorolac 0.4% ophth sol to T4
- Lokelma add QL
- loteprednol gel to T4
- malathion to T3
- Mavyret 50-20 mg granules add QL
- meclizine add PA
- memantine ER 7, 14, 21 mg cap add QL
- memantine-donepezil 14-10 mg ER cap add QL
- methsuximide to T4
- methylphenidate OSM 18, 27 mg tab add QL
- Namzaric 7-10 mg ER cap add QL
- Nexletol PA type from new starts to all
- Nexlizet PA type from new starts to all
- nortriptyline oral solution to T4
- Nurtec to T5
- Orgovyx add PA
- Orkambi add QL
- perphenazine-amitriptyline to T4 (T4 on STD 2026)
- pimecrolimus 1% cream add QL
- pyridostigmine oral solution to T4 (T4 on STD 2026)
- quinidine gluconate to T4
- Qulipta to T5
- risedronate 5, 30 mg, DR 35 mg tab to T4
- rivaroxaban 2.5 mg to T3, add QL
- Scemblix 40 mg tab lower QL
- sertraline oral concentrate to T4 (T4 on STD 2026)
- sodium-magnesium-potassium sulfates solution to T4
- terbinafine tab add yearly QL
- teriflunomide to T4 (T4 on STD 2026)
- Ticovac to T4
- TobraDex ointment to T4 (T4 on STD 2026)
- topiramate oral solution add ST thru sprinkle cap
- trandolapril-verapamil to T4
- Ubrelvy to T5
- Xdemvy change to annual QL
- Xiidra add QL

#### ***Negative changes (STD only)***

- alfuzosin ER to T2
- amlodipine-valsartan-hydrochlorothiazide to T4
- budesonide 3 mg ER cap to T4
- clobazam tab to T4
- Droxia to T4
- dutasteride to T2
- ibandronate to T2
- mycophenolate sodium DR tab to T4

- olmesartan-amlodipine-hydrochlorothiazide to T4
- rasagiline to T4
- tacrolimus ointment to T3
- tazarotene 0.1% cream to T4
- tetrabenazine to T4
- ursodiol to T4

#### ***Negative changes (C-SNP only)***

- sacubitril-valsartan to T3

#### ***Formulary adds (both ENH and STD)***

- Avtozma T5
- clindamycin-BPO 1.2%-2.5% gel T2
- clobetasol foam T2
- fluticasone-vilanterol T3
- Gemtesa T3 w/QL
- Janumet and Janumet XR T3
- Otezla and Otezla XR (all 2026 NF) T5 w/QL
- Starjemza T4
- Wegovy tab T3, PA, QL

#### ***Formulary adds (STD only)***

- adapalene-BPO 1%-2.5% gel T2 (T2 on ENH)
- desonide lotion T2
- desoximetasone 0.25% spray T2
- Inbrija T5 w/PA (T5 w/PA on ENH)
- methylphenidate OSM T4
- Wegovy SC T3, PA, QL

#### ***Positive changes (both ENH and STD)***

- ambrisentan to T3 (ENH) or T4 (STD)
- budesonide 9mg ER tab to T4, add QL
- caspofungin IV remove PA BvD
- darunavir to T2
- dihydroergotamine nasal spray to T4
- Elmiron to T4, add QL
- eslicarbazepine to T4
- etravirine 100 mg tab to T4
- everolimus 0.5, 0.75 mg tab to T4, add QL
- Evrysdi PA type from all to new starts
- ezetimibe-simvastatin 10-80 mg tab remove PA
- fondaparinux 5, 7.5 mg to T4
- fosamprenavir to T4
- ketoconazole tab remove PA
- maraviroc to T4
- meropenem IV to T2
- nevirapine 200 mg tab to T2

- Otezla 30 mg and starter pack remove PA, add QL
- posaconazole 100 mg DR tab to T4
- simvastatin 80 mg tab remove PA
- tetrabenazine 12.5 mg tab increase QL
- Tyenne remove PA
- Vowst increase PA duration
- Vraylar to T3
- Xifaxan 550 mg tab to T3

***Positive changes (ENH only)***

- desonide lotion to T2
- desoximetasone 0.25% spray to T2
- ivabradine tab to T3
- Wegovy SC to T3